BCL2 and cancer: Accordingly, BH3 mimetics designed to block the sequestration capacity of anti-apoptotic BCL-2 proteins towards BH3-containing pro-apoptotic interactors sensitize cancer cells to NK- and T-cell-mediated killing [20].